Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06HSC
|
|||
Former ID |
DNC007651
|
|||
Drug Name |
Folate gamma-L-phenylalaninehydroxamic acid
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C28H29N9O7
|
|||
Canonical SMILES |
C1=CC=C(C=C1)CC(C(=O)NO)NC(=O)CCC(C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=O)NC(=N4)N
|
|||
InChI |
1S/C28H29N9O7/c29-28-35-23-22(26(41)36-28)32-18(14-31-23)13-30-17-8-6-16(7-9-17)24(39)34-19(27(42)43)10-11-21(38)33-20(25(40)37-44)12-15-4-2-1-3-5-15/h1-9,14,19-20,30,44H,10-13H2,(H,33,38)(H,34,39)(H,37,40)(H,42,43)(H3,29,31,35,36,41)/t19-,20-/m0/s1
|
|||
InChIKey |
WYBGJFMKGROIBY-PMACEKPBSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Matrix metalloproteinase-7 (MMP-7) | Target Info | Inhibitor | [1] |
KEGG Pathway | Wnt signaling pathway | |||
NetPath Pathway | Wnt Signaling Pathway | |||
Panther Pathway | Alzheimer disease-presenilin pathway | |||
Wnt signaling pathway | ||||
CCKR signaling map ST | ||||
Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | |||
p75(NTR)-mediated signaling | ||||
Syndecan-1-mediated signaling events | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
Assembly of collagen fibrils and other multimeric structures | ||||
WikiPathways | Wnt Signaling Pathway and Pluripotency | |||
Activation of Matrix Metalloproteinases | ||||
AGE/RAGE pathway | ||||
Matrix Metalloproteinases |
References | Top | |||
---|---|---|---|---|
REF 1 | Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.